United States Biotechnology & Medical Research

Replimune Group Inc (REPL)

Track

Over the past 90 days, Replimune Group Inc. insiders have engaged in seven transactions, all of which were sales totaling approximately $585,026. Key executives, including the CEO and CFO, participated in these disposals. This activity follows a period of significant stock price appreciation of 359.9%, occurring ahead of the company's recent earnings report.
Ticker: REPL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Replimune Group Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sarchi Christopher
Chief Commercial Officer
1 sale — total 110,880 USD
Planned sale 1 Jun 2026
Value US$756,597.45 | Price 365.20 | Shares 16,617
Sale 18 May 2026
Value US$3,577,132.41 | Price 71.21 | Shares 98,804
Sale 18 May 2026
Value US$40,101.52 | Price 5.08 | Shares 7,894
Sale 18 May 2026
Value US$189,605.92 | Price 5.08 | Shares 37,324
Sale 18 May 2026
Value US$43,820.08 | Price 5.08 | Shares 8,626
Sale 18 May 2026
Value US$89,697.56 | Price 5.08 | Shares 17,657
Sale 18 May 2026
Value US$71,236.84 | Price 5.08 | Shares 14,023
Planned sale 2 Apr 2026
Value US$52,065.00 | Price 8.01 | Shares 6,500
Proposed sale 2 Apr 2026
Value US$142,450.00 | Price 7.70 | Shares 18,500
Sale 9 Dec 2025
Value US$32,957.60 | Price 10.40 | Shares 3,169
Proposed sale 9 Dec 2025
Value US$32,842.00 | Price 10.38 | Shares 3,164
Planned sale 2 Dec 2025
Value US$111,300.00 | Price 11.13 | Shares 10,000
Proposed sale 2 Dec 2025
Value US$111,303.00 | Price 11.13 | Shares 10,000
Sale 17 Nov 2025
Value US$65,956.80 | Price 9.10 | Shares 7,248
Sale 17 Nov 2025
Value US$47,392.80 | Price 9.10 | Shares 5,208
Sale 15 Aug 2025
Value US$49,156.98 | Price 5.37 | Shares 9,154
Sale 20 May 2025
Value US$30,179.45 | Price 8.05 | Shares 3,749
Sale 20 May 2025
Value US$26,460.35 | Price 8.05 | Shares 3,287
Sale 20 May 2025
Value US$260,168.74 | Price 8.06 | Shares 32,279
Sale 20 May 2025
Value US$64,093.12 | Price 8.06 | Shares 7,952
Sale 20 May 2025
Value US$20,406.75 | Price 8.05 | Shares 2,535
Sale 20 May 2025
Value US$202,346.30 | Price 8.06 | Shares 25,105
Planned sale 16 Dec 2024
Value US$124,200.00 | Price 12.42 | Shares 10,000
Proposed sale 16 Dec 2024
Value US$188,550.00 | Price 12.57 | Shares 15,000
Sale 18 Nov 2024
Value US$78,111.88 | Price 10.78 | Shares 7,246
Sale 18 Nov 2024
Value US$56,131.46 | Price 10.78 | Shares 5,207
Sale 16 Aug 2024
Value US$90,988.84 | Price 10.18 | Shares 8,938
Planned sale 7 Jun 2024
Value US$119,107.50 | Price 7.50 | Shares 15,881
Proposed sale 7 Jun 2024
Value US$119,185.00 | Price 7.50 | Shares 15,881
Proposed sale 23 May 2024
Value US$472,680.00 | Price 5.93 | Shares 79,710
Sale 16 May 2024
Value US$74,172.08 | Price 6.47 | Shares 11,464
Sale 16 May 2024
Value US$113,969.05 | Price 6.47 | Shares 17,615
Sale 16 May 2024
Value US$130,655.18 | Price 6.47 | Shares 20,194
Sale 16 May 2024
Value US$130,655.18 | Price 6.47 | Shares 20,194
Sale 16 May 2024
Value US$14,350.46 | Price 6.47 | Shares 2,218
Sale 16 May 2024
Value US$14,350.46 | Price 6.47 | Shares 2,218
Sale 16 May 2024
Value US$14,868.06 | Price 6.47 | Shares 2,298
Sale 16 May 2024
Value US$14,868.06 | Price 6.47 | Shares 2,298
Sale 16 May 2024
Value US$41,194.49 | Price 6.47 | Shares 6,367
Sale 16 May 2024
Value US$245,394.16 | Price 6.47 | Shares 37,928
Sale 16 Nov 2023
Value US$79,857.96 | Price 10.92 | Shares 7,313
Sale 16 Nov 2023
Value US$57,384.60 | Price 10.92 | Shares 5,255
Planned sale 12 Sep 2023
Value US$6,000.00 | Price 20.00 | Shares 300
Planned sale 11 Sep 2023
Value US$107,213.58 | Price 20.01 | Shares 5,358
Planned sale 22 Aug 2023
Value US$372,186.00 | Price 20.01 | Shares 18,600
Planned sale 11 Aug 2023
Value US$28,000.00 | Price 20.00 | Shares 1,400
Planned sale 10 Jul 2023
Value US$43,866.24 | Price 21.12 | Shares 2,077
Planned sale 10 Jul 2023
Value US$387,674.49 | Price 21.63 | Shares 17,923
Proposed sale 10 Jul 2023
Value US$1,694,400.00 | Price 21.18 | Shares 80,000
Planned sale 13 Jun 2023
Value US$19,158.65 | Price 23.45 | Shares 817
Planned sale 13 Jun 2023
Value US$290,236.30 | Price 24.10 | Shares 12,043
Planned sale 13 Jun 2023
Value US$12,962.32 | Price 23.44 | Shares 553
Planned sale 13 Jun 2023
Value US$124,045.95 | Price 24.11 | Shares 5,145
Proposed sale 13 Jun 2023
Value US$527,297.00 | Price 23.45 | Shares 22,486
Proposed sale 13 Jun 2023
Value US$555,999.00 | Price 23.45 | Shares 23,710
Sale 16 May 2023
Value US$141,891.05 | Price 18.05 | Shares 7,861
Sale 16 May 2023
Value US$194,488.75 | Price 18.05 | Shares 10,775
Sale 16 May 2023
Value US$13,916.55 | Price 18.05 | Shares 771
Sale 16 May 2023
Value US$281,128.75 | Price 18.05 | Shares 15,575
Sale 16 May 2023
Value US$107,686.30 | Price 18.05 | Shares 5,966
Sale 16 May 2023
Value US$204,885.55 | Price 18.05 | Shares 11,351
Sale 16 May 2023
Value US$323,131.10 | Price 18.05 | Shares 17,902
Sale 16 May 2023
Value US$220,336.35 | Price 18.05 | Shares 12,207
Planned sale 9 Dec 2022
Value US$375,450.00 | Price 25.03 | Shares 15,000
Sale 16 May 2022
Value US$83,702.83 | Price 14.59 | Shares 5,737
Sale 16 May 2022
Value US$92,267.16 | Price 14.59 | Shares 6,324
Sale 16 May 2022
Value US$155,923.33 | Price 14.59 | Shares 10,687
Sale 16 May 2022
Value US$140,530.88 | Price 14.59 | Shares 9,632
Sale 16 May 2022
Value US$51,167.13 | Price 14.59 | Shares 3,507
Sale 16 May 2022
Value US$79,851.07 | Price 14.59 | Shares 5,473
Sale 16 May 2022
Value US$50,131.24 | Price 14.59 | Shares 3,436
Sale 16 Mar 2022
Value US$602,749.10 | Price 15.55 | Shares 38,762
Sale 16 Mar 2022
Value US$95,503.78 | Price 15.31 | Shares 6,238
Sale 15 Mar 2022
Value US$703,800.00 | Price 15.64 | Shares 45,000
Sale 14 Mar 2022
Value US$254,430.00 | Price 15.42 | Shares 16,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-03 2026-06-01 PlS Planned sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
16,617 -22.6%
365.20
US$756,597 		16,617 -22.6% 365.20 US$756,597
2026-05-20 2026-05-18 S Sale
2.5
Hill Emily Luisa

Chief Financial Officer

Officer
98,804 -7.9%
71.21
US$3,577,132 		98,804 -7.9% 71.21 US$3,577,132
2026-05-20 2026-05-18 S Sale
1.6
Schwendenman Andrew

Chief Accounting Officer

Officer
45,830 -28.7%
380.53
US$4,738,057 		45,830 -28.7% 380.53 US$4,738,057
2026-05-20 2026-05-18 S Sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
37,324 -4.8%
5.08
US$189,606 		37,324 -4.8% 5.08 US$189,606
2026-05-20 2026-05-18 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
8,626 -4.3%
5.08
US$43,820 		8,626 -4.3% 5.08 US$43,820
2026-05-20 2026-05-18 S Sale
2.1
Astley-Sparke Philip
Non-Executive Director
17,657 -1.2%
5.08
US$89,698 		17,657 -1.2% 5.08 US$89,698
2026-05-20 2026-05-18 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
14,023 -5.6%
5.08
US$71,237 		14,023 -5.6% 5.08 US$71,237
2026-04-06 2026-04-02 PlS Planned sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
6,500 -4.1%
8.01
US$52,065 		6,500 -4.1% 8.01 US$52,065
2026-04-02 2026-04-02 PrS Proposed sale
2.8
Christopher Sarchi

Officer

Officer
18,500
7.70
US$142,450 		18,500 7.70 US$142,450
2025-12-11 2025-12-09 S Sale
3.5
Dhingra Kapil
Non-Executive Director
3,169 -100.0%
10.40
US$32,958 		3,169 -100.0% 10.40 US$32,958
2025-12-09 2025-12-09 PrS Proposed sale
3.5
Kapil Dhingra

Director

Non-Executive Director
3,164
10.38
US$32,842 		3,164 10.38 US$32,842
2025-12-04 2025-12-02 PlS Planned sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
10,000 -2.9%
11.13
US$111,300 		10,000 -2.9% 11.13 US$111,300
2025-12-02 2025-12-02 PrS Proposed sale
1.8
Sushil Patel

Chief Strategy Officer

Officer
10,000
11.13
US$111,303 		10,000 11.13 US$111,303
2025-11-19 2025-11-17 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
7,248 -4.9%
9.10
US$65,957 		7,248 -4.9% 9.10 US$65,957
2025-11-19 2025-11-17 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
5,208 -4.1%
9.10
US$47,393 		5,208 -4.1% 9.10 US$47,393
2025-08-19 2025-08-15 S Sale
2.5
Hill Emily Luisa

Chief Financial Officer

Officer
9,154 -6.4%
5.37
US$49,157 		9,154 -6.4% 5.37 US$49,157
2025-05-22 2025-05-20 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
3,749 -2.8%
8.05
US$30,179 		3,749 -2.8% 8.05 US$30,179
2025-05-22 2025-05-20 S Sale
1.6
Schwendenman Andrew

Chief Accounting Officer

Officer
3,287 -4.6%
8.05
US$26,460 		3,287 -4.6% 8.05 US$26,460
2025-05-22 2025-05-20 S Sale
2.1
Astley-Sparke Philip
Non-Executive Director
32,279 -2.2%
8.06
US$260,169 		32,279 -2.2% 8.06 US$260,169
2025-05-22 2025-05-20 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
7,952 -5.1%
8.06
US$64,093 		7,952 -5.1% 8.06 US$64,093
2025-05-22 2025-05-20 S Sale
2.5
Hill Emily Luisa

Chief Financial Officer

Officer
2,535 -1.7%
8.05
US$20,407 		2,535 -1.7% 8.05 US$20,407
2025-05-22 2025-05-20 S Sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
25,105 -6.8%
8.06
US$202,346 		25,105 -6.8% 8.06 US$202,346
2024-12-18 2024-12-16 PlS Planned sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
10,000 -4.7%
12.42
US$124,200 		10,000 -4.7% 12.42 US$124,200
2024-12-16 2024-12-16 PrS Proposed sale
1.8
Sushil Patel

Chief Strategy Officer

Officer
15,000
12.57
US$188,550 		15,000 12.57 US$188,550
2024-11-20 2024-11-18 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
7,246 -6.2%
10.78
US$78,112 		7,246 -6.2% 10.78 US$78,112
2024-11-20 2024-11-18 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
5,207 -5.6%
10.78
US$56,131 		5,207 -5.6% 10.78 US$56,131
2024-08-19 2024-08-16 S Sale
2.5
Hill Emily Luisa

Chief Financial Officer

Officer
8,938 -8.1%
10.18
US$90,989 		8,938 -8.1% 10.18 US$90,989
2024-06-10 2024-06-07 PlS Planned sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
15,881 -11.9%
7.50
US$119,108 		15,881 -11.9% 7.50 US$119,108
2024-06-07 2024-06-07 PrS Proposed sale
2.9
Konstantinos Xynos

Officer

Officer
15,881
7.50
US$119,185 		15,881 7.50 US$119,185
2024-05-23 2024-05-23 PrS Proposed sale
1.2
Pamela Esposito

Officer

Officer
79,710
5.93
US$472,680 		79,710 5.93 US$472,680
2024-05-20 2024-05-16 S Sale
1.4
Coffin Robert
Non-Executive Director
11,464 -0.6%
6.47
US$74,172 		11,464 -0.6% 6.47 US$74,172
2024-05-20 2024-05-16 S Sale
1.4
Love Colin

Chief Operating Officer

Officer
17,615 -2.2%
6.47
US$113,969 		17,615 -2.2% 6.47 US$113,969
2024-05-20 2024-05-16 S Sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
20,194 -8.7%
6.47
US$130,655 		20,194 -8.7% 6.47 US$130,655
2024-05-20 2024-05-16 S Sale
1.8
Patel Sushil

Chief Executive Officer

Executive Director
20,194 -8.7%
6.47
US$130,655 		20,194 -8.7% 6.47 US$130,655
2024-05-20 2024-05-16 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
2,218 -2.3%
6.47
US$14,350 		2,218 -2.3% 6.47 US$14,350
2024-05-20 2024-05-16 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
2,218 -2.3%
6.47
US$14,350 		2,218 -2.3% 6.47 US$14,350
2024-05-20 2024-05-16 S Sale
1.6
Schwendenman Andrew

Chief Accounting Officer

Officer
2,298 -5.7%
6.47
US$14,868 		2,298 -5.7% 6.47 US$14,868
2024-05-20 2024-05-16 S Sale
1.6
Schwendenman Andrew

Chief Accounting Officer

Officer
2,298 -5.7%
6.47
US$14,868 		2,298 -5.7% 6.47 US$14,868
2024-05-20 2024-05-16 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
6,367 -4.6%
6.47
US$41,194 		6,367 -4.6% 6.47 US$41,194
2024-05-20 2024-05-16 S Sale
2.1
Astley-Sparke Philip

Executive Chairman

Executive Director
37,928 -2.5%
6.47
US$245,394 		37,928 -2.5% 6.47 US$245,394
2023-11-17 2023-11-16 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
7,313 -6.1%
10.92
US$79,858 		7,313 -6.1% 10.92 US$79,858
2023-11-17 2023-11-16 S Sale
2.8
Sarchi Christopher

Chief Commercial Officer

Officer
5,255 -6.8%
10.92
US$57,385 		5,255 -6.8% 10.92 US$57,385
2023-09-13 2023-09-12 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
300 -0.1%
20.00
US$6,000 		300 -0.1% 20.00 US$6,000
2023-09-13 2023-09-11 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
5,358 -2.0%
20.01
US$107,214 		5,358 -2.0% 20.01 US$107,214
2023-08-24 2023-08-22 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
18,600 -6.6%
20.01
US$372,186 		18,600 -6.6% 20.01 US$372,186
2023-08-15 2023-08-11 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
1,400 -0.5%
20.00
US$28,000 		1,400 -0.5% 20.00 US$28,000
2023-07-11 2023-07-10 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
2,077 -0.8%
21.12
US$43,866 		2,077 -0.8% 21.12 US$43,866
2023-07-11 2023-07-10 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
17,923 -6.3%
21.63
US$387,674 		17,923 -6.3% 21.63 US$387,674
2023-07-10 2023-07-10 PrS Proposed sale
1.2
Pamela Esposito

Officer

Officer
80,000
21.18
US$1,694,400 		80,000 21.18 US$1,694,400
2023-06-15 2023-06-13 PlS Planned sale
2.0
Lewis Tanya

Chief Dev. Op. Officer

Officer
817 -0.6%
23.45
US$19,159 		817 -0.6% 23.45 US$19,159
2023-06-15 2023-06-13 PlS Planned sale
2.0
Lewis Tanya

Chief Dev. Op. Officer

Officer
12,043 -8.1%
24.10
US$290,236 		12,043 -8.1% 24.10 US$290,236
2023-06-15 2023-06-13 PlS Planned sale
1.8
Patel Sushil

Chief Strategy Officer

Officer
553 -0.4%
23.44
US$12,962 		553 -0.4% 23.44 US$12,962
2023-06-15 2023-06-13 PlS Planned sale
1.8
Patel Sushil

Chief Strategy Officer

Officer
5,145 -3.3%
24.11
US$124,046 		5,145 -3.3% 24.11 US$124,046
2023-06-13 2023-06-13 PrS Proposed sale
2.0
Tanya Lewis

Affiliate
22,486
23.45
US$527,297 		22,486 23.45 US$527,297
2023-06-13 2023-06-13 PrS Proposed sale
1.8
Sushil Patel

Affiliate
23,710
23.45
US$555,999 		23,710 23.45 US$555,999
2023-05-18 2023-05-16 S Sale
1.4
Coffin Robert

President & Chief R&D Officer

Executive Director
7,861 -0.4%
18.05
US$141,891 		7,861 -0.4% 18.05 US$141,891
2023-05-18 2023-05-16 S Sale
1.4
Love Colin

Chief Operating Officer

Officer
10,775 -1.3%
18.05
US$194,489 		10,775 -1.3% 18.05 US$194,489
2023-05-18 2023-05-16 S Sale
2.9
Xynos Konstantinos

Chief Medical Officer

Officer
771 -0.6%
18.05
US$13,917 		771 -0.6% 18.05 US$13,917
2023-05-18 2023-05-16 S Sale
1.8
Patel Sushil

Chief Strategy Officer

Officer
15,575 -9.2%
18.05
US$281,129 		15,575 -9.2% 18.05 US$281,129
2023-05-18 2023-05-16 S Sale
1.2
Esposito Pamela

Chief Business Officer

Officer
5,966 -2.2%
18.05
US$107,686 		5,966 -2.2% 18.05 US$107,686
2023-05-18 2023-05-16 S Sale
2.4
Franchi Jean M.

Chief Financial Officer

Officer
11,351 -8.1%
18.05
US$204,886 		11,351 -8.1% 18.05 US$204,886
2023-05-18 2023-05-16 S Sale
2.1
Astley-Sparke Philip

Chief Executive Officer

Executive Director
17,902 -1.2%
18.05
US$323,131 		17,902 -1.2% 18.05 US$323,131
2023-05-18 2023-05-16 S Sale
2.0
Lewis Tanya

Chief Dev. Op. Officer

Officer
12,207 -7.6%
18.05
US$220,336 		12,207 -7.6% 18.05 US$220,336
2022-12-13 2022-12-09 PlS Planned sale
1.2
Esposito Pamela

Chief Business Officer

Officer
15,000 -6.1%
25.03
US$375,450 		15,000 -6.1% 25.03 US$375,450
2022-05-18 2022-05-16 S Sale
1.4
Coffin Robert

President & Chief R&D Officer

Executive Director
5,737 -0.3%
14.59
US$83,703 		5,737 -0.3% 14.59 US$83,703
2022-05-18 2022-05-16 S Sale
1.4
Love Colin

Chief Operating Officer

Officer
6,324 -0.8%
14.59
US$92,267 		6,324 -0.8% 14.59 US$92,267
2022-05-18 2022-05-16 S Sale
1.8
Patel Sushil

Chief Commercial Officer

Officer
10,687 -7.6%
14.59
US$155,923 		10,687 -7.6% 14.59 US$155,923
2022-05-18 2022-05-16 S Sale
2.1
Astley-Sparke Philip

Chief Executive Officer

Executive Director
9,632 -0.7%
14.59
US$140,531 		9,632 -0.7% 14.59 US$140,531
2022-05-18 2022-05-16 S Sale
1.2
Esposito Pamela

Chief Business Officer

Officer
3,507 -1.5%
14.59
US$51,167 		3,507 -1.5% 14.59 US$51,167
2022-05-18 2022-05-16 S Sale
2.0
Lewis Tanya

Chief Dev. Op Officer

Officer
5,473 -4.3%
14.59
US$79,851 		5,473 -4.3% 14.59 US$79,851
2022-05-18 2022-05-16 S Sale
2.4
Franchi Jean M.

Chief Financial Officer

Officer
3,436 -3.5%
14.59
US$50,131 		3,436 -3.5% 14.59 US$50,131
2022-03-16 2022-03-16 S Sale
1.6
Omega Fund IV, L.P.
Large shareholder
38,762 -0.8%
15.55
US$602,749 		38,762 -0.8% 15.55 US$602,749
2022-03-16 2022-03-16 S Sale
1.6
Omega Fund IV, L.P.
Large shareholder
6,238 -0.1%
15.31
US$95,504 		6,238 -0.1% 15.31 US$95,504
2022-03-16 2022-03-15 S Sale
1.6
Omega Fund IV, L.P.
Large shareholder
45,000 -0.9%
15.64
US$703,800 		45,000 -0.9% 15.64 US$703,800
2022-03-16 2022-03-14 S Sale
1.6
Omega Fund IV, L.P.
Large shareholder
16,500 -0.3%
15.42
US$254,430 		16,500 -0.3% 15.42 US$254,430
Explore more

More insider trading research around Replimune Group Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America